(Photo courtesy: White House video screen grab) The Trump administrations latest agreements with two major drugmakers to lower the cost of expensive weight loss and diabetes drugs, [...] Please Login or Become a Paid Subscriber to View this Content If you are not yet a paid subscriber, please Subscribe now For questions about subscriptions or technical assistance, please contact Reshma Eggleston at [email protected] .
This design reduces hypoglycemic risk compared to sulfonylureas, though risk does not disappear entirely, especially when combined with other glucose-lowering medications
Stratified analyses by sex, ethnicity, race, age, BMI, HbA1c, and eGFR yielded consistent findings across all subgroups
D.DiasR
The combination of LBPs and exercise was particularly effective in lowering long-term cardiovascular risk, suggesting that lifestyle factors may enhance the cardiovascular benefits of LBPs